Our mission on drug discovery and pharma research
MEDINA is leader in Drug Discovery from Microbial Natural Product Libraries and internal High Throughput Screening (HTS) programs are focused on strategic therapeutic areas: Infectious and Parasitic Diseases, Oncology and Neurodegeneration.
Fundación MEDINA, DNDi and Institut Pasteur Korea announce their research partnership in leishmaniasis and Chagas disease
Click on above image and keep up to date with our latest news.
MEDINA offers a wide panel of research services for the discovery and development of new natural products and biomarkers, with application in the pharmaceutical, agri-food and cosmetic sectors, and other biotechnological sectors.
MEDINA discovers bio-active molecules, drug leads for unmet medical needs and high value biotechnological products.
We are exclusive owners of one of the world´s largest Microbial Collections (190,000 microbial strains), and Natural Products Libraries (over 135,000 extracts & fractions).
Latest news
Granada, Spain September 28th 2020 Fundación MEDINA, DNDi and Institut Pasteur Korea announce new funding from “la Caixa” Health Research for research partnership to discover new natural products against leishmaniasis and Chagas disease Fundación MEDINA, the Drugs for...
Granada: 28 May 2020 MEDINA, Almirall and UC3M to research new treatments for rare genetic diseases. Fundación MEDINA, Almirall, S.A. (ALM) and the University Carlos III Madrid (UC3M) have launched a project to find new treatments for recessive dystrophic...
MEDINA is a drug discovery organization and a partner site of the European research infrastructure EU-OPENSCREEN (www.eu-openscreen.eu). Leveraging our drug discovery expertise, the potential of our natural product libraries and the high throughput screening and...